ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Investors Create Boston Pharma

by Michael McCoy
November 30, 2015 | APPEARED IN VOLUME 93, ISSUE 47

A new company, Boston Pharmaceuticals, has been created by Gurnet Point Capital, the investment firm formed earlier this year by Swiss entrepreneur Ernesto Bertarelli and led by Christopher Viehbacher, former CEO of Sanofi. Gurnet says it is committing $600 million to Boston Pharma so the new firm can acquire clinical assets from academic, biotech, and pharmaceutical groups. The firm says it is agnostic to therapeutic area, focusing instead on validated mechanisms of action. It will be led by Viehbacher and Robert Armstrong, former head of external R&D at Eli Lilly & Co.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment